Memantine Hydrochloride Accord Healthcare (Memantine Hydrochloride)

The drug acts as a non‑competitive antagonist at the NMDA receptor, blocking excessive calcium influx caused by overstimulation with glutamate. This reduces excitotoxic neuronal damage and helps preserve synaptic activity in neurodegenerative conditions.

The dosing regimen for Memantine Hydrochloride is determined by the prescribing clinician based on the patient’s condition, renal function, and response to therapy. Dosage adjustments are made according to professional guidelines and individual patient needs.

Safety data for Memantine Hydrochloride in pregnancy and lactation are limited. The medication should only be used if the potential benefit justifies the potential risk to the fetus or infant, and decisions should be made in consultation with a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Memantine belongs to the NMDA receptor antagonist class, differing from cholinesterase inhibitors such as donepezil. While cholinesterase inhibitors increase acetylcholine levels, Memantine reduces glutamate‑mediated excitotoxicity. In practice, clinicians may use Memantine alone or in combination with a cholinesterase inhibitor for broader symptom control.

Store the product at ambient temperature, preferably below 25 °C. Keep it in the original packaging to protect from moisture and light. Do not refrigerate or freeze the tablets, and keep them out of reach of children.

Memantine Hydrochloride is taken orally, usually as a tablet. It should be swallowed whole with water and can be taken with or without food, following the schedule prescribed by the treating physician.

Serious adverse events, although rare, include seizures, severe skin reactions such as Stevens‑Johnson syndrome, significant cardiac arrhythmias, and emergence of suicidal thoughts. Patients should be monitored closely for any of these symptoms and seek immediate medical attention if they occur.

Memantine is contraindicated in patients with known hypersensitivity to the drug. Caution is advised for individuals with severe renal or hepatic impairment, uncontrolled epilepsy, or those taking other NMDA antagonists. A healthcare professional should evaluate suitability before initiating therapy.